Aethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system, including removal of COVID-19 virus, associated variants, and related exosomes. Aethlon Medical, Inc. has a collaboration with the University of Pittsburgh Medical Center Hillman Cancer Center for studies related to head and neck cancer. The company was founded in 1999 and is based in San Diego, California.
Wall Street Analysts Forecast Growth
Separately, StockNews.com raised shares of Aethlon Medical to a "sell" rating in a research report on Friday, August 12th.
Aethlon Medical Stock Down 6.6 %
Shares of AEMD traded down $0.09 during mid-day trading on Thursday, hitting $1.27. The company had a trading volume of 996,024 shares, compared to its average volume of 1,845,548. Aethlon Medical has a 1-year low of $0.88 and a 1-year high of $5.99. The business's 50-day simple moving average is $1.16 and its 200-day simple moving average is $1.25. The stock has a market cap of $21.13 million, a PE ratio of -1.71 and a beta of 0.77.
Aethlon Medical (NASDAQ:AEMD - Get Rating) last posted its quarterly earnings results on Tuesday, June 28th. The medical equipment provider reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.13). Aethlon Medical had a negative net margin of 3,542.86% and a negative return on equity of 59.57%. The business had revenue of $0.01 million during the quarter, compared to analysts' expectations of $1.02 million. On average, sell-side analysts expect that Aethlon Medical will post 0.56 earnings per share for the current year.